4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > MedKoo/Plinabulin/10mg/202040
商品详细MedKoo/Plinabulin/10mg/202040
MedKoo/Plinabulin/10mg/202040
MedKoo/Plinabulin/10mg/202040
商品编号: 202040
品牌: MedKoo
市场价: ¥1800.00
美元价: 1080.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

Plinabulin
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:202040

CAS#:714272-27-2

Description:Plinabulin is a VDA of novel structure in having been derived from a marine microbial source, as opposed to terrestrial sources for other VDAs. Plinabulin binds to the colchicine binding site of b-tubulin preventing polymerization and disrupting the cytoplasmic microtubule network. Plinabulin has been shown to produce anti-tumor activity in animal models as a single agent and synergistically with other chemotherapy agents including taxanes. Overall, preclinical studies indicated plinabulin had a favorable safety and activity profile leading to the initiation of clinical trials. Favorable data from early clinical studies lead to the initiation of a Phase 2 clinical trial program..

Price and Availability

SizePriceShipping out timeQuantity
10mgUSD 902 Weeks
25mgUSD 1502 Weeks
50mgUSD 2502 Weeks
100mgUSD 4502 Weeks
200mgUSD 7502 Weeks
500mgUSD 13502 Weeks
1gUSD 19502 Weeks
2gUSD 29502 Weeks
5gUSD 49502 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

Plinabulin, purity > 98%, is in stock. Note: the estimated shipping out time for order > 5g may be 2 weeks.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 202040Name: PlinabulinCAS#: 714272-27-2Chemical Formula: C19H20N4O2Exact Mass: 336.15863Molecular Weight: 336.39Elemental Analysis:C, 67.84; H, 5.99; N, 16.66; O, 9.51

Synonym:NPI 2358; NPI2358; NPI-2358; Plinabulin

IUPAC/Chemical Name:(3E,6E)-3-benzylidene-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene)piperazine-2,5-dione

InChi Key:UNRCMCRRFYFGFX-AOEKMSOUSA-N

InChi Code:InChI=1S/C19H20N4O2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11H,1-3H3,(H,20,21)(H,22,25)(H,23,24)/b14-9+,15-10+

SMILES Code:O=C(/C(NC/1=O)=CC2=CC=CC=C2)NC1=CC3=C(C(C)(C)C)NC=N3

Technical Data

Appearance:
Yellow solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View current batch of CoA

QC Data:
View NMR, View HPLC, View MS

Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

References

1: Yakushiji F, Tanaka H, Muguruma K, Iwahashi T,Yamazaki Y, Hayashi Y. Prodrug study of plinabulin using a clickstrategy focused on the effects of a replaceable water-solubilizingmoiety. Chem Pharm Bull (Tokyo). 2012;60(7):877-81. PubMed PMID:22790821.

2: Yakushiji F, Tanaka H, Muguruma K, Iwahashi T, Yamazaki Y, Hayashi Y.Water-soluble prodrug of antimicrotubule agent plinabulin: effectivestrategy with click chemistry. Chemistry. 2011 Nov 4;17(45):12587-90.doi: 10.1002/chem.201102293. Epub 2011 Sep 29. PubMed PMID: 21956869.

3: Bertelsen LB, Shen YY, Nielsen T, Stødkilde-Jørgensen H, Lloyd GK,Siemann DW, Horsman MR. Vascular effects of plinabulin (NPI-2358) andthe influence on tumour response when given alone or combined withradiation. Int J Radiat Biol. 2011 Nov;87(11):1126-34. doi:10.3109/09553002.2011.605418. PubMed PMID: 21815749; PubMed CentralPMCID: PMC3509771.

4: Singh AV, Bandi M, Raje N, Richardson P, Palladino MA, Chauhan D,Anderson KC. A novel vascular disrupting agent plinabulin triggersJNK-mediated apoptosis and inhibits angiogenesis in multiple myelomacells. Blood. 2011 May 26;117(21):5692-700. doi:10.1182/blood-2010-12-323857. Epub 2011 Mar 31. PubMed PMID: 21454451;PubMed Central PMCID: PMC3110026.

5: Millward M, Mainwaring P, Mita A, Federico K, Lloyd GK, Reddinger N,Nawrocki S, Mita M, Spear MA. Phase 1 study of the novel vasculardisrupting agent plinabulin (NPI-2358) and docetaxel. Invest New Drugs.2012 Jun;30(3):1065-73. doi: 10.1007/s10637-011-9642-4. Epub 2011 Feb16. PubMed PMID: 21327495.

6: Mita MM, Spear MA, Yee LK, Mita AC, Heath EI, Papadopoulos KP,Federico KC, Reich SD, Romero O, Malburg L, Pilat M, Lloyd GK, NeuteboomST, Cropp G, Ashton E, LoRusso PM. Phase 1 first-in-human trial of thevascular disrupting agent plinabulin(NPI-2358) in patients with solidtumors or lymphomas. Clin Cancer Res. 2010 Dec 1;16(23):5892-9. doi:10.1158/1078-0432.CCR-10-1096. PubMed PMID: 21138873.

7: Yamazaki Y, Kido Y, Hidaka K, Yasui H, Kiso Y, Yakushiji F, HayashiY. Tubulin photoaffinity labeling study with a plinabulin chemical probepossessing a biotin tag at the oxazole. Bioorg Med Chem. 2011 Jan1;19(1):595-602. doi: 10.1016/j.bmc.2010.10.055. Epub 2010 Oct 31.PubMed PMID: 21106379.

8: Yamazaki Y, Sumikura M, Hidaka K, Yasui H, Kiso Y, Yakushiji F,Hayashi Y. Anti-microtubule "plinabulin" chemical probe KPU-244-B3labeled both alpha- and beta-tubulin. Bioorg Med Chem. 2010 May1;18(9):3169-74. doi: 10.1016/j.bmc.2010.03.037. Epub 2010 Mar 23.PubMed PMID: 20395148.

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。